NEW YORK, N.Y., July 15, 2024 – PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq: SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin’s lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A:...
![PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results](https://prismmediawire.com/wp-content/uploads/2024/07/Newsroom-12.png)
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix’s HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
read more